Lichen China
LICN
1 hedge funds and large institutions have $985 invested in Lichen China in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
44% more capital invested
Capital invested by funds: $683 → $985 (+$302)
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$240 |
| 2 |
Morgan Stanley
New York
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $985 | -$240 | -73 | -30% |
|
|
2
Morgan Stanley
New York
| – | -$6 | -2 | Closed |
|
LICN Hedge Fund Activity: Q1 2026 in Review
1 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q1 2026, worth a combined $985 — up 44% from $683 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LICN and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was UBS Group, cutting an estimated $240.
- 1 institutional investor held Lichen China (LICN) as of Q1 2026, down from 2 in Q4 2025.
- Funds reported $985 of Lichen China stock for Q1 2026, up 44% quarter-over-quarter.
- 0 funds opened new Lichen China positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Lichen China seller in Q1 2026 was UBS Group, an estimated $240 sold.
Based on aggregated 13F filings for Q1 2026.